{
    "2020-11-26": [
        [
            {
                "time": "",
                "original_text": "【新康界每周投资策略】医药生物行业分析系列——第三方医学诊断（实验室）（ICL）",
                "features": {
                    "keywords": [
                        "新康界",
                        "投资策略",
                        "医药生物",
                        "第三方医学诊断",
                        "实验室",
                        "ICL"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【新康界每周投资策略】科创板细则落地，或可分拆上市的医药上市公司有哪些？",
                "features": {
                    "keywords": [
                        "新康界",
                        "投资策略",
                        "科创板",
                        "细则落地",
                        "分拆上市",
                        "医药上市公司"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}